Cellular immunity (T-cell subset using monoclonal antibody) in tuberculosis, melioidosis, pasteurellosis, penicilliosis; and role of levamisole and isoprinosine.
In vitro and in vivo evaluation of cellular immunity (T-cell subset--using monoclonal antibody--immunofluorescent staining technique; E-rosette formation to 2.4-Dinitrochlorobenzene reaction) were made in tuberculosis, melioidosis, pasteurellosis and penicilliosis. The data demonstrate depressed cellular immunity especially a significant decrease in numbers of T-helper cells and T-helper/T-suppressor subset ratio fell to less than 1.0. Of greater importance, in tuberculous patients and patients with melioidosis treated with levamisole, 150 mg/day, twice a week, along with a specific antitubercular or antimicrobial agent for appropriate duration, improved faster both clinically, microbiologically and in cellular immunity.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007239:Infections / Q000188:drug therapy / Q000276:immunology*; D007542:Inosine Pranobex / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use; D008297:Male; D008554:Melioidosis / Q000276:immunology; D008875:Middle Aged; D009181:Mycoses / Q000276:immunology; D010326:Pasteurella Infections / Q000276:immunology; D010407:Penicillium; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000276:immunology
D000911:Antibodies, Monoclonal; D007978:Levamisole; D007542:Inosine Pranobex